Fulcrum Therapeutics (FULC) , a clinical-stage company, is expected to report third-quarter 2024 results early next month. The Zacks Consensus Estimate for the to-be-reported quarter's loss is pinned at 40 cents per share. The company currently does not have any marketed products and does not record any revenues. The Zacks Consensus Estimate for Fulcrum's loss per share has narrowed from 46 cents to 28 cents for 2024 over the past 60 days, while that for 2025 has narrowed from $1.51 to $1.14. FULC Estimate ...

Core Viewpoint - Fulcrum Therapeutics (FULC) has experienced a significant stock decline of 58% over the past month, underperforming compared to the industry and the S&P 500, primarily due to disappointing results from a late-stage study of its candidate losmapimod for facioscapulohumeral muscular dystrophy (FSHD) [1][2][3] Company Performance - The phase III REACH study for FSHD did not meet its primary endpoint, failing to show a change from baseline in relative surface area compared to placebo at week 48, leading to the cessation of losmapimod's development in this indication [3][4] - Despite the setback with losmapimod, Fulcrum has another promising candidate, pociredir, which is being developed for sickle cell disease (SCD) [4][5] Pipeline Development - Pociredir is an investigational oral small-molecule inhibitor developed using Fulcrum's proprietary technology, FulcrumSeek, and is currently in a phase Ib study with four dosage strengths [6][7] - Early data for pociredir in SCD has shown proof-of-concept by increasing HbF levels, indicating potential benefits for patients, and it has been well-tolerated with no serious adverse events reported [7][8] Market Potential - The SCD market presents significant growth opportunities due to unmet medical needs and regulatory incentives, with pociredir already receiving Fast Track and Orphan Drug designations in the U.S. [8][12] - Competitors in the SCD market include Vertex and CRISPR Therapeutics, which have recently launched their gene therapy, highlighting the competitive landscape [9] Valuation and Earnings Estimates - Fulcrum's stock appears attractive from a valuation perspective, trading at a price/book value ratio of 0.81, below the industry average of 3.89 and its own 5-year mean of 2.25 [10] - Analysts have narrowed the loss per share estimates for Fulcrum, indicating an improving outlook, with estimates for 2024 reduced from 46 cents to 28 cents and for 2025 from $1.51 to $1.14 [11][12] Investment Consideration - Despite the recent pipeline setback, the potential of pociredir for SCD could drive growth, making Fulcrum a stock worth considering for investors looking for opportunities in the biotech sector [11][13]

FMR LLC (Trades, Portfolio) Transaction Overview - FMR LLC (Trades, Portfolio) sold 3,605,932 shares of Fulcrum Therapeutics Inc (FULC) on September 30, 2024, reducing its holdings to 1,724,014 shares [1] - The shares were traded at $3.57, reflecting a strategic adjustment in the firm's portfolio [1] - This transaction reduced FMR LLC's stake in Fulcrum Therapeutics to 2.76% [5] FMR LLC (Trades, Portfolio) Background - FMR LLC, also known as Fidelity, was established in 1946 and has a strong focus on growth potential and innovative investment strategies [2] - The firm manages a vast portfolio with significant holdings in technology and healthcare sectors, including major companies like Apple Inc and Microsoft Corp [2] - As of June 30, 2024, FMR LLC's top holdings include NVIDIA Corp ($129.0B), Microsoft Corp ($96.8B), and Apple Inc ($72.8B) [3] Fulcrum Therapeutics Inc Overview - Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for complex diseases such as muscular dystrophy and sickle cell disease [4] - The company went public on July 18, 2019, and currently has a market capitalization of $224.955 million [4] - Fulcrum's stock price is $3.605, significantly below its GF Value of $48.74 [4] Market Performance and Valuation of Fulcrum Therapeutics - Fulcrum Therapeutics has experienced a 50% year-to-date price decrease and a 75.14% drop since its IPO [6] - The company's GF Score is 54/100, indicating poor future performance potential [6] - Fulcrum ranks 1/10 in Profitability and 0/10 in Growth, further highlighting its challenges [6] Biotechnology Sector and FMR LLC's Strategy - FMR LLC has historically allocated a significant portion of its portfolio to the healthcare sector, with biotechnology being a key focus [7] - The recent reduction in Fulcrum Therapeutics holdings suggests a possible realignment of FMR LLC's investment strategy within the volatile biotechnology sector [7] Future Outlook for Fulcrum Therapeutics - Analysts remain cautious about Fulcrum Therapeutics' future due to its financial health and market challenges [8] - The strategic reduction by FMR LLC may indicate broader concerns about the biotechnology sector's near-term prospects [8] Conclusion - The transaction by FMR LLC represents a significant realignment of its investment in Fulcrum Therapeutics, reflecting the firm's adaptive portfolio management strategy [9] - This move is indicative of FMR LLC's response to the evolving dynamics of the biotechnology sector [9]

Group 1 - Fulcrum Therapeutics, Inc. (FULC) has experienced significant selling pressure, resulting in a 65.6% loss over the past four weeks, but it is now considered to be in oversold territory [1] - Wall Street analysts anticipate that FULC will report better earnings than previously predicted, with a consensus EPS estimate increase of 24.8% over the last 30 days [3] - The stock's Relative Strength Index (RSI) is currently at 20.49, indicating a potential trend reversal as the heavy selling appears to be exhausting itself [3] Group 2 - FULC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, suggesting a strong potential for price appreciation [3]

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FULC. Investigation Details On September 12, 2024, Fulcrum announced that "its Phase 3 REACH trial evaluating losma ...

Shares of Fulcrum Therapeutics, Inc. (FULC) plunged 61.1% on Sept. 12 after the company announced disappointing top-line data from the phase III REACH study, which evaluated its pipeline candidate, losmapimod, for treating patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disease. Currently, there are no treatments approved for the given indication. The study did not meet its primary endpoint as treatment with losmapimod failed to demonstrate a change from baseline in rela ...

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences: Wells Fargo Healthcare Conference Wednesday, September 4, 2024 Boston, MA Morgan Stanley 22nd Annual Global Healthcare Conference Frid ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other juri ...

• Cash Position: As of June 30, 2024, cash, cash equivalents, and marketable securities were $273.8 million, as compared to $236.2 million as of December 31, 2023. The increase in our cash position is due to the $80.0 million upfront payment received from Sanofi in the second quarter of 2024, partially offset by cash used to fund our operating activities in 2024. • Collaboration Revenue: Collaboration revenue was $80.0 million for the three months ended June 30, 2024, as compared to $0.9 million for the thr ...

― Conference call and webcast scheduled for 8:00 a.m. ET today ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ― CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for ...